CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.
CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.
No indication information available.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.